Zobrazeno 1 - 10
of 11
pro vyhledávání: '"James Savery"'
Autor:
Stephen Goldrick, Haneen Alosert, Clare Lovelady, Nicholas J. Bond, Tarik Senussi, Diane Hatton, John Klein, Matthew Cheeks, Richard Turner, James Savery, Suzanne S. Farid
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 11 (2023)
Cell line development is an essential stage in biopharmaceutical development that often lies on the critical path. Failure to fully characterise the lead clone during initial screening can lead to lengthy project delays during scale-up, which can pot
Externí odkaz:
https://doaj.org/article/b8b9e6ce0bbe496d96efa8a7b7ef2a67
Autor:
Cristiana Campa, Thierry Pronce, Marilena Paludi, Jos Weusten, Laura Conway, James Savery, Christine Richards, Didier Clénet
Publikováno v:
Vaccines, Vol 9, Iss 10, p 1114 (2021)
Stability assessment of pharmaceuticals in specific storage and shipment conditions is a key requirement to ensure that safe and efficacious products are administered to patients. This is particularly relevant for vaccines, with numerous vaccines str
Externí odkaz:
https://doaj.org/article/e535e1ce50244c25baef30cd3ddd55e9
Autor:
Thierry Pronce, Cristiana Campa, Jos Weusten, Didier Clénet, Laura Conway, James Savery, Christine Richards, Marilena Paludi
Publikováno v:
Vaccines, Vol 9, Iss 1114, p 1114 (2021)
Vaccines
Volume 9
Issue 10
Vaccines
Volume 9
Issue 10
Stability assessment of pharmaceuticals in specific storage and shipment conditions is a key requirement to ensure that safe and efficacious products are administered to patients. This is particularly relevant for vaccines, with numerous vaccines str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bf4f3aa194d7dc44132d0147eee07c
https://www.mdpi.com/2076-393X/9/10/1114
https://www.mdpi.com/2076-393X/9/10/1114
Autor:
Haneen Alosert, James Savery, Jennifer Rheaume, Matthew Cheeks, Richard Turner, Christopher Spencer, Suzanne S. Farid, Stephen Goldrick
Publikováno v:
Biotechnology Journal. 17:2100609
Data Integrity (DI) in the highly regulated biopharmaceutical sector is of paramount importance to ensure decisions on meeting product specifications are accurate and hence assure patient safety and product quality. The challenge of ensuring DI withi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8a9b173a44dc8441d6dd4953c08040f
https://doi.org/10.1002/biot.202100609
https://doi.org/10.1002/biot.202100609
Autor:
Rahul Pradhan, Diane Hatton, Nitin Agarwal, Viv Lindo, Guillermo Miro-Quesada, James Savery, Jan Kemper, Jihong Wang, Dimitra Serfiotis-Mitsa, Alison Mason, Sanjeev Ahuja, Allen D. Bosley
Publikováno v:
Biotechnology progressREFERENCES. 35(5)
Glycation, the nonenzymatic reaction between the reducing sugar glucose and the primary amine residues on amino acid side chains, commonly occurs in the cell culture supernatant during production of therapeutic monoclonal antibodies (mAbs). While gly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78576925f4515148fc53701127bf048
https://pubmed.ncbi.nlm.nih.gov/31180183
https://pubmed.ncbi.nlm.nih.gov/31180183
Autor:
Raghavan Venkat, James Savery, Ronald Schoner, Krista Evans, Bhargavi Rajan, Thomas Albanetti, Christopher Groves, Guillermo Miro-Quesada
Publikováno v:
Biotechnology Progress
Regulatory authorities require that cell lines used in commercial production of recombinant proteins must be derived from a single cell progenitor or clone. The limiting dilution method of cell cloning required multiple rounds of low‐density cell p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee75c7aea4841f3faf348369bbd3873
http://europepmc.org/articles/PMC5054913
http://europepmc.org/articles/PMC5054913
Autor:
Krista Evans, James Savery
Publikováno v:
Biotechnology progress. 34(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::209d88c14a4b33d4a326565127d9a349
https://pubmed.ncbi.nlm.nih.gov/27111698
https://pubmed.ncbi.nlm.nih.gov/27111698
Publikováno v:
Biotechnology Progress. 23:1383-1393
Biopharmaceutical companies with large portfolios of clinical and commercial products typically need to allocate production across several multiproduct facilities, including third party contract manufacturers. This poses several capacity planning cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::239f5417b2ed09b14add3bf2b66724d8
https://doi.org/10.1021/bp0701362
https://doi.org/10.1021/bp0701362
Publikováno v:
Biotechnology Progress. 21:1478-1489
Regulatory pressures and capacity constraints are forcing the biopharmaceutical industry to consider employing multiproduct manufacturing facilities running on a campaign basis. The need for such flexible and cost-effective manufacture poses a signif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b491fd035c1f7a61b4fb8a6f8dd007a
https://doi.org/10.1021/bp0501571
https://doi.org/10.1021/bp0501571
Autor:
Lazaros G. Papageorgiou, James Savery, Kais Lakhdar, Nigel J. Titchener-Hooker, Suzanne S. Farid
Manufacturers in the biopharmaceutical industry face greater scheduling and planning challenges as the trend of employing multiproduct manufacturing facilities continues to grow. These challenges are complicated by the randomness inherent in the biop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::183ac44c6e6de738664d4fb0d46db982
https://doi.org/10.1016/s1570-7946(06)80353-6
https://doi.org/10.1016/s1570-7946(06)80353-6
